MIRM:NSD-Mirum Pharmaceuticals Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 40.29

Change

-0.13 (-0.32)%

Market Cap

N/A

Volume

0.31M

Analyst Target

USD 48.71
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-17 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
REGN Regeneron Pharmaceuticals Inc

-7.94 (-0.69%)

USD 127.14B
VRTX Vertex Pharmaceuticals Inc

-7.10 (-1.48%)

USD 125.27B
ALNY Alnylam Pharmaceuticals Inc

-1.31 (-0.48%)

USD 35.24B
ARGX argenx NV ADR

+6.84 (+1.31%)

USD 32.19B
MRNA Moderna Inc

-2.13 (-2.96%)

USD 26.25B
SMMT Summit Therapeutics PLC

-1.66 (-6.33%)

USD 23.47B
BGNE BeiGene Ltd

-0.23 (-0.12%)

USD 21.94B
RPRX Royalty Pharma Plc

-0.03 (-0.11%)

USD 16.45B
BMRN Biomarin Pharmaceutical Inc

+0.59 (+0.84%)

USD 16.16B
UTHR United Therapeutics Corporatio..

-2.43 (-0.70%)

USD 15.09B

ETFs Containing MIRM

BBP Virtus LifeSci Biotech Pr.. 2.31 % 0.79 %

-0.19 (0.30%)

USD 0.02B
IWC iShares Micro-Cap ETF 0.00 % 0.60 %

+0.37 (+0.30%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 36.48% 78% C+ 87% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 36.48% 78% C+ 87% B+
Trailing 12 Months  
Capital Gain 29.97% 71% C- 79% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 29.97% 70% C- 77% C+
Trailing 5 Years  
Capital Gain 339.85% 95% A 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 339.85% 95% A 95% A
Average Annual (5 Year Horizon)  
Capital Gain 25.04% 74% C 81% B-
Dividend Return 25.04% 74% C 80% B-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 41.76% 69% C- 44% F
Risk Adjusted Return 59.97% 97% N/A 84% B
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector